<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624593</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1088</org_study_id>
    <nct_id>NCT05624593</nct_id>
  </id_info>
  <brief_title>P200TE and Predicate Agreement and Precision Study</brief_title>
  <official_title>P200TE Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optos, PLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective comparative, randomized, single center study to assess agreement&#xD;
      and precision of the P200TE in comparison to the predicate device in normal subjects,&#xD;
      subjects with glaucoma, and subjects with retinal disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the P200TE and predicate device measurements of full retinal thickness.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the P200TE and predicate device measurements of retinal nerve fiber layer thickness (μm).</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the P200TE and predicate device measurements of ganglion cell complex thickness (μm).</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the P200TE and predicate device measurements of optic disc (disc area, rim area, cup-to-disc area, cup-to-disc vertical, cup-to-disc horizontal)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the P200TE and predicate device measurements of full retinal thickness</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the P200TE and predicate device measurements of retinal nerve fiber layer thickness.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the P200TE and predicate device measurements of ganglion cell complex thickness</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the P200TE and predicate device measurements of optic disc (disc area, rim area, cup-to-disc area, cup-to-disc vertical, cup-to-disc horizontal)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Normal</condition>
  <condition>Retina Disease</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>P200TE</intervention_name>
    <description>The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.</description>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Predicate</intervention_name>
    <description>The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.</description>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group&#xD;
&#xD;
          1. Subjects 22 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. Subjects with normal eye examinations in both eyes on the date of the study visit as&#xD;
             observed with a 90 diopter lens&#xD;
&#xD;
          4. BCVA 20/40 or better (each eye) on the date of the study visit&#xD;
&#xD;
        Exclusion Criteria for Normal Group&#xD;
&#xD;
          1. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          2. Subjects not able to obtain acceptable OCT images due to ocular media opacity or other&#xD;
             reasons&#xD;
&#xD;
          3. Subject has a condition or is in a situation which the investigator feels may put the&#xD;
             subject at significant risk, may confound the study results, or may interfere&#xD;
             significantly with the subject's participation in the study&#xD;
&#xD;
          4. Presence of any ocular pathology except for cataract in either eye&#xD;
&#xD;
        Inclusion Criteria for Glaucoma Group&#xD;
&#xD;
          1. Subjects 22 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. BCVA 20/40 or better in the study eye&#xD;
&#xD;
          4. History of Visual field defects within the previous year from the study visit or&#xD;
             measured the day of the study visit consistent with glaucomatous optic nerve damage&#xD;
             with at least one of the following two findings:&#xD;
&#xD;
               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an&#xD;
                  expected location of the visual field depressed below the 5% level, at least 1 of&#xD;
                  which is depressed below the 1% level;&#xD;
&#xD;
               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;&#xD;
&#xD;
          5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or&#xD;
             retinal nerve fiber layer structural abnormalities:&#xD;
&#xD;
               1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim,&#xD;
                  especially at the inferior or superior poles with or without disc hemorrhage;&#xD;
&#xD;
               2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural&#xD;
                  tissue&#xD;
&#xD;
        Exclusion Criteria for Glaucoma Group&#xD;
&#xD;
          1. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          2. Subjects not able to obtain acceptable OCT images due to ocular media opacity or other&#xD;
             reasons&#xD;
&#xD;
          3. Subject has a condition or is in a situation which the investigator feels may put the&#xD;
             subject at significant risk, may confound the study results, or may interfere&#xD;
             significantly with the subject's participation in the study&#xD;
&#xD;
          4. No reliable Humphrey Field Analyzer (HFA) visual field (24-2 Sita Standard or Fast,&#xD;
             white on white) result within the past year of the study visit, defined as fixation&#xD;
             losses &gt; 33% or false positives &gt; 33%, or false negatives &gt; 33% in the study eye&#xD;
&#xD;
          5. Presence of any ocular pathology except glaucoma in the study eye&#xD;
&#xD;
        Inclusion Criteria for Retina Disease Group&#xD;
&#xD;
          1. Subjects 22 years of age or older on the date of informed consent&#xD;
&#xD;
          2. Subjects able to understand the written informed consent and willing to participate as&#xD;
             evidenced by signing the informed consent&#xD;
&#xD;
          3. Subjects presenting at the site with retinal disease&#xD;
&#xD;
          4. BCVA 20/400 or better in the study eye&#xD;
&#xD;
          5. Diagnosis of some type of retinal pathology by investigator, may include, but not&#xD;
             limited to: Macular Degeneration (including patients with drusen and geographic&#xD;
             atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic&#xD;
             Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others&#xD;
&#xD;
        Exclusion Criteria for Retinal Disease Group&#xD;
&#xD;
          1. Subjects unable to tolerate ophthalmic imaging&#xD;
&#xD;
          2. Subjects not able to obtain acceptable OCT images due to ocular media opacity or other&#xD;
             reasons&#xD;
&#xD;
          3. Subject has a condition or is in a situation which the investigator feels may put the&#xD;
             subject at significant risk, may confound the study results, or may interfere&#xD;
             significantly with the subject's participation in the study&#xD;
&#xD;
          4. Presence of glaucoma or any ocular pathology other than a retinal pathology (e.g.,&#xD;
             cornea pathology) in the study eye as determined by self report and/or investigator&#xD;
             assessment at the study visit;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eylse Nylin</last_name>
    <phone>312-949-7000</phone>
    <email>enylin@ico.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Martinez</last_name>
    <phone>312-949-7000</phone>
    <email>jemartinez@ico.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Nylin</last_name>
      <phone>312-949-7324</phone>
      <email>enylin@ico.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Chaglasian, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

